Overexpression of LOX and COX enzymes has long been associatedwith tumor progression [6–8],and targets for those pathways have been a primary interest in research fortherapeutics agents [9–11].However, specific COX-2 inhibitors have been associated with cardiovasculartoxicity [12–15].It has also been reported that products of the LOX pathway and inhibitors ofthis pathway may induce activity of peroxisome-proliferator-activated receptorgamma (PPARγ) [9, 16, 17]. The gene discussed is PPARG; the disease is neoplasm.